Caricamento...
Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials
Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial infarction in patients with acute coronary syndromes and in patients undergoing percutaneous coronary intervention, the benefit is achieved only during the infusion period. Or...
Salvato in:
| Pubblicato in: | Clin Cardiol |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley Periodicals, Inc.
2009
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654967/ https://ncbi.nlm.nih.gov/pubmed/11129681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960231105 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|